Prof. Kathy Pritchard-Jones, President

Kathy Pritchard-Jones is President of SIOP and Professor of Paediatric Oncology at University College London (UCL) Great Ormond Street Institute of Child Health, London, UK. She is an internationally recognised expert in childhood kidney cancers, where she has extensive experience of running multi-centre and international clinical trials and translational research. She also works with epidemiologists and healthcare data scientists for international benchmarking and outcomes research. She has a track record of enabling partnership working to deliver quality improvement in complex care and to accelerate research across both adult and childhood cancer services. Throughout her career she has been an active member of the work of the national Children’s Cancer and Leukaemia Group (CCLG), the International Society of Paediatric Oncology (SIOP) and SIOP Europe. She has published over 250 articles in the field of childhood cancer.

Dr. Gregory Reaman, Treasurer

Gregory H. Reaman, M.D. is Professor of Pediatrics at George Washington University School of Medicine and Health Sciences in Washington, D.C. and a member of the Division of Hematology-Oncology and Executive Director Emeritus of the Center for Cancer and Blood Disorders at the Children’s National Medical Center, which he directed for more than 17 years. He is the Inaugural Chair of the Children’s Oncology Group (COG) having served in this capacity from 2000 through 2010. The COG is comprised of over 200 member institutions, dedicated to clinical, translational, and epidemiology research in childhood cancer. Prior to this, he was the Vice Chair for Scientific Affairs and the Associate Chair for New Agent Studies of the Children’s Cancer Group (CCG) for 10 years and directed the CCG Phase I Consortium. He joined the FDA in 2011 as the Associate Director for Oncology Sciences in the Office of Hematology and Oncology in the Center for Drug Evaluation and Research. Dr. Reaman serves or has served on several editorial boards: he served as an Associate Editor of Cancer and Leukemia and Lymphoma. He served on the Board of Directors of the American Cancer Society and chaired its Task Force on Children and Cancer and has served on the Board of Directors of the American Society of Clinical Oncology (ASCO) and has served on numerous ASCO committees. He was elected to the Board of SIOP as treasurer in 2011. His research interests are in the biology and treatment of childhood acute leukemia and new drug development for pediatric cancers. He is the author of more than 350 peer – reviewed manuscripts and 20 book chapters and 3 text books.

Prof. Eric Bouffet, Advocacy Chair and former SIOP President

Dr. Eric Bouffet is a Professor of Paediatrics at the University of Toronto; Garron Family Chair in Childhood Cancer Research; and Head of the Neuro-Oncology Section in the Division of Haematology/Oncology at The Hospital for Sick Children in Toronto, Canada. He is a Senior Associate Scientist in the Research Institute at the Hospital for Sick Children. He was the Former President for the International Society of Paediatric Oncology (SIOP) with a term from 2016-2019, and is now the Advocacy Chair for SIOP. From 1998-2001 he was co-Chairman of the Brain Tumour Committee of SIOP, and he is Chair of the Canadian Paediatric Brain Tumour Consortium since 2003. Dr. Bouffet is a member of the steering committee of the Brain Tumour Committee of the Children’s Oncology Group (COG).

Dr. Scott Howard, Secretary-General

After training in internal medicine, pediatrics, and epidemiology at the University of Tennessee and completing a hematology/oncology fellowship at St. Jude Children’s Research Hospital, Dr. Howard worked there for 16 years treating children with leukemia and lymphoma and conducting research in oncology supportive care and international oncology. He is particularly interested in management of patients with leukemia and lymphoma and all aspects of oncology supportive care (e.g. infectious complications, tumor lysis syndrome, thrombosis, venous access complications, endocrine and bone toxicities), and has experience facilitating local, national, and regional clinical research in a number of middle-income countries. In 2015, he founded Resonance Oncology to improve care for cancer patients everywhere, but especially in low- and middle-income countries (LMIC), through research, healthcare information technology, education, and development of regional and global networks for care and research. To complement these efforts, Scott conducts translational research at the University of Memphis (Memphis, Tennessee, USA) using large animal models of chemotherapy toxicity. Dr. Howard has a long history of working with SIOP colleagues to address issues in LMIC and to foster education and network building.  He currently chairs the Clinical Practice Guidelines Committee of the American Society of Pediatric Hematology Oncology and the SIOP PODC Twinning Working Group, whose goal is to promote local, regional, and global collaboration.

Dr. Khan Muhammad Saghir, Co-Chair of Pediatric Oncology Developing Countries (PODC)

Muhhamad Saghir Khan (MD) is co chair of SIOP PODC. He is currently working as Specialist Pediatric Hematology/Oncology Physician at Tawam Hospital Al Ain United Arab Emirates. He completed his medical education including Pediatric Oncology fellowship from Pakistan, and had served as General Secretary of PSPO (Pakistan Society of Pediatric Oncology) during 2013-2014. He is former co chair of SIOP PODC Supportive Care working group (2014-2018). He has actively been involved in Pediatric Oncology East Mediterranean group (POEM) since it’s foundation. Saghir has contributed as leader/member of scientific committees for several National, Regional and International Pediatric Oncology Conferences. He played vital role as Scientific Co Chair of SIOP Asia 2019 held at Abu Dhabi.

Dr. Sandra Luna-Fineman, Co-Chair of Pediatric Oncology Developing Countries (PODC)

Dr. Lindsay Frazier, Continental President North America

Dr. A. Lindsay Frazier M.D., Sc.M. is a Pediatric Oncologist at the Dana-Faber Cancer Institute and Boston Children’s Hospital, Professor of Pediatrics at Harvard Medical School, also holds an appointment in epidemiology at the Harvard School of Public Health. Dr. Frazier leads the Childhood Oncology Registries project for the Global Health Initiative of the Dana-Farber Children’s Cancer and Blood Disorders Center. In 2014, population-based cancer registries were begun in Guatemala and El Salvador. These foundational projects will serve as the basis for cancer epidemiology in Central America. The expectation is that these projects will expand to the other two low-middle income countries in Central America, Nicaragua and Honduras, in 2016. Dr. Frazier also serves as the chair of the Medical Advisory Board of the Massachusetts State Cancer Registry. She co-led an international consensus workshop on how to record the stage of pediatric cancer in population-based pediatric cancer registries, funded by NCI, at SIOP in Toronto in 2014. The Toronto Pediatric Cancer Staging Guidelines have been endorsed by the TNM committee, UICC, and IARC and will be published in Lancet Oncology in 2016. Dr. Frazier’s clinical expertise within pediatric oncology are germ cell tumors (GCT). Dr. Frazier has served on the steering committee of the Childrens’ Oncology Group’s (COG) germ cell committee since 1995 and assumed leadership of the committee in 2007. Her role includes oversight of all current COG protocols and the development of the strategic initiatives for future protocols across the spectrum of disease.

Prof. Pamela Kearns, Continental President Europe

Prof. Pam Kearns is Chair of Clinical Paediatric Oncology at the University of Birmingham, where is Director of the Institute of Cancer and Genomic Sciences and Director of the Cancer Research UK Clinical Trials Unit (CRCTU). She is also an Honorary Consultant Paediatric Oncologist at Birmingham Women and Children’s Hospital. As Director of CRCTU, she leads the research strategy for UK’s largest cancer trials unit, delivering a trials portfolio of over 120 multi-centre & international cancer trials for a wide-range of cancers, occurring in all children, young people and adults across 347 centres in 21 countries. Notably, she leads the Cancer Research UK funded National Children’s Cancer Trials Teams. In 2015, she was appointed as a Senior Clinical Advisor to Cancer Research UK. In January 2019, Professor Kearns became President of the European Society of Paediatric Oncology (SIOP Europe). She also sits on the Boards for both the European consortium for Innovative Therapeutics for Children with Cancer (ITCC); a consortium developing early phase clinical trials for childhood cancers through International partnerships and ACCELERATE; a multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.  Through her leading roles within the University of Birmingham, Cancer Research UK and SIOP-Europe, she provides national and international expert advice and guidance on research governance, regulatory affairs and research ethics in relation to clinical trials. She leads the ITCC’s European consortium of academic trial sponsors from 7 countries developing and delivering a platform for efficient and accelerated delivery of academic early phase childhood cancer trials in UK & across Europe.

Arturo Moreno, Continental President Latin America

Leila Hessissen, Continental President Africa

Laila Hessissen is a Professor of Pediatrics in the Medical School of Rabat, Morocco, where she has been a faculty member since 2000. She also works as a Pediatric Hematology Oncologist at the Pediatric Hematology Oncology Centre of Rabat. Laila received her Pediatric Oncology University Diploma from the Paris-Sud University in France in 2000. Laila is the former President of the Moroccan Society of Pediatric Oncology Hematology, Vice General Secretary of the French-African Group of Pediatric Oncology (GFAOP), and she is the Continental President of SIOP-Africa. Since 2014, Laila has been involved in the creation and supervision of a Certified Diploma of Pediatric Oncology for clinicians in French-Speaking African Countries. This program takes place at the Mohammed 5 University of Rabat and is recognized by the Paris-Sud University in France. Through this program, she has developed the e-GFAOP e-learning platform for participants in the diploma program as well as a network of practical training sites. She is interested in pediatric brain tumors, genetic predisposition, and metronomic chemotherapy.

Rashmi Dalvi, Continental President Asia

Rashmi Dalvi MD DCH is presently MUHS Professor and Head, Department of Pediatrics & Pediatric Hematology Oncology, at the Bombay Hospital Institute of Medical Sciences & Visiting Consultant at NH-SRCC Children’s hospital and PHO-BMT Department of LTMG Medical College Hospital, in Mumbai. An alumnus of Seth GS Medical College/KEM Hospital, she trained in PHO In India (1988), and at the Children’s Hospitals of Michigan (1996) & Philadelphia (UICC-ICRETT 2001). She was among the earliest to develop and promote PHO subspecialty in India, and has been involved in academics & clinical practice in PHO & Immunology for over 30 years, as university faculty & previously at BJ Wadia Hospital for Children, with numerous publications & presentations to her credit. She has special interest in Lymphomas, Nutrition & Supportive care, Registries, Histiocytic disorders & HLH. She has been actively involved with SIOP & the Pediatric Oncology in Developing Countries Committee since 1992; including as founder member of the SIOP-India project, “NTP-PPO” addressing Early Diagnosis & Treatment Abandonment in children with cancer. She has held various positions including, Chair of National PHO Society, India(2009-12), Chair, SIOP-PODC Committee on Education & Training(2010-13), Chair-Coordinator NTP-PPO (2007-2012), LOC member for SIOP Asia 2002, Delhi & SIOP 2007, Mumbai, Presently she is Chair of the SIOP Asia Conference, Mumbai 2020, and Member, ICON Ethics Committee & Stem Cell Committee, King Edward Memorial Hospital.

Prof. Michael Sullivan, Continental President Oceania and Co-Chair-Elect of PODC

Michael Sullivan is a Paediatric Oncologist and Neuro-Oncologist in the Children’s Cancer Centre, Royal Children’s Hospital, Melbourne, a Professor of Paediatrics, Department of Paediatrics, University of Melbourne, and an Honorary Professor of Paediatrics, University of Otago, New Zealand. A graduate of the University of Otago Medical School, he trained in Paediatrics and Paediatric Oncology in New Zealand and Australia and did his PhD in the Epigenetics of Wilms tumour. He has extensive experience in clinical trials and translational research, in particular hepatoblastoma. He is an executive member of SIOPEL and a member of the CHIC liver tumour consortium, SIOPEN, COG and ANZCHOG. Prior to moving to Melbourne in 2013, he was Chair of the New Zealand National Children’s Cancer Network and led the development of the New Zealand Late Effects Assessment Program and the New Zealand Children’s Cancer Registry. Dr. Sullivan has a long-term commitment to Paediatric Oncology in Developing Countries (PODC), especially in the Pacific and Oceania. Since 2006, he has been a member of the NZ Pacific Islands Working Group supporting the care of children with cancer in Fiji and the Pacific Islands, and more recently, he led the establishment of twinning programs with PNG, Timor-Leste and Laos. He is a member of the Melbourne Children’s Global Health and leads the Global Paediatric Oncology Program at the Royal Children’s Hospital. Dr. Sullivan is a member of the SIOP Advocacy Working Group, is the SIOP Liaison for the WHO Global Initiative for Childhood Cancer and Continental President for SIOP Oceania. He is currently the co-chair of the SIOP PODC Adapted Treatment Working Group, and in 2020 he was elected Co-Chair elect of SIOP-PODC.

Donna Johnston, Local Organizing Committee Chair

Donna Johnston is a Pediatric Hematologist/Oncologist at the Children’s Hospital of Eastern Ontario and the Chief of the Division of Hematology/Oncology.  She is a full Professor of Pediatrics at the University of Ottawa. She completed medical school at Queen’s University, her pediatric residency at the University of Ottawa, and her hematology/oncology fellowship at the Fred Hutchinson Cancer Research Center in Seattle Washington. She is an active participant in the Children’s Oncology Group both as the site PI and as a member of the Cancer Control and Myeloid Committees.  Her main areas of oncology expertise are in AML, neuro-oncology, supportive care and palliative care. She is involved clinical research, most of which involves supportive care for oncology patients.

Prof. Dr. Stephen Hunger, Treasurer Elect

Dr. Hunger is Professor of Pediatrics, the Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics, Chief of the Division of Pediatric Oncology and Director of the Center for Childhood Cancer Research at the Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania. Dr. Hunger is Professor of Pediatrics, the Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics, Chief of the Division of Pediatric Oncology and Director of the Center for Childhood Cancer Research at the Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania. Dr. Hunger is an internationally recognized expert in the molecular genetics and treatment of childhood ALL and was Chair of the Children’s Oncology Group ALL Disease Committee from 2008-15 and leads the COG ALL TARGET project, which has led to major new insights into the genetics of ALL and identified important new therapeutic targets. Dr. Hunger also has an interest in global health with a focus on improving treatment for children with ALL in low and middle income countries.

Incoming Members of the Board of Directors:

Dr. Julia Challinor, Secretary-General Elect

Julia Challinor, (RN, PhD, MS in Education and MS in Med Anthropology) serves as a consultant for multiple international projects for childhood cancer and pediatric oncology nursing, including the APHON Spanish Chemotherapy/Biotherapy course in Latin America. She was the Educational Liaison for children with cancer and those who had survived their disease at the University of California, San Francisco from 1993-2003. During 1994-2006, she also headed A Tomorrow for Children Foundation and worked in partnership with pediatric oncology centers that are members of the Asociación de Hemato-Oncología Pediátrica de Centro America (AHOPCA), collaborating with Jude Children’s Research Hospital, the Pediatric Oncology Group of Ontario (Canada) (POGO), and the Monza International School of Pediatric Hematology/Oncology (Italy) (MISPHO). Recently she has participated in pediatric oncology nursing initiatives in Ethiopia and India. As the International Society of Paediatric Oncology (SIOP) Advocacy Officer Julia has participated in the WHO Global Childhood Initiative for Childhood Cancer (GICC) since 2018, the WHO (GICC) workshop in Lima Peru in 2019 and ongoing related nursing projects in the country. Other tasks include a continued role in WHO GICC nursing issues and the SIOP Global Mapping of Pediatric Oncology Services project.

Lisa Morrissey, Chair of the Nursing Committee

Lisa is a nurse leader in the Dana-Farber/Boston Children’s Hospital (DF/BCH) Cancer and Blood Disorders Program in Boston, MA. She holds an MSN degree in Nursing Administration from Northeastern University, and a MPH in Healthcare Management from Harvard School of Public Health. Lisa is the Nurse Manager for the Inpatient Hematology/Oncology/Research at BCH, and Director of the BHC Global Nurse Fellowship program. She has led several nursing global partnerships in resource-limited countries including Tanzania, Central America, the Dominican Republic and Myanmar, promoting education, professionalism and collaboration for pediatric oncology nurses. Lisa is co-chair of the SIOP PODC Nursing workgroup and an active member of the SIOP Nursing Baseline Standards Task Force.

Dr. Joyce Kambugu, Continental President Elect-Africa

Dr Joyce Balagadde Kambugu is a leading peadiatric oncologist in East and Central Africa with more than 10 years’ experience in this field. She is based at Uganda Cancer Institute (UCI), the national referral cancer treatment, research and training center in Uganda where she directs the peadiatric oncology service. She did her basic and graduate (Paediatrics and Child Health) training at Makerere University in Uganda; and  fellowship training in peadiatric oncology at the University of Cape Town (Red Cross War Memorial Children’s hospital). While at the UCI Joyce spear headed the establishment of a dedicated paediatric oncology service and later a fellowship program in paediatric oncology. She is now engaged in extending paediatric cancer services to regional hospitals in the country and modification of the National Cancer Control Plan. Joyce is a passionate advocate for paediatric cancer in developing countries.

Dr. Hiroki Hori, Continental President Elect-Asia

Dr. Hiroki Hori is Professor at Graduate School of Medicine, Mie University in Tsu, Japan and a member of Japanese Society of Pediatric Hematology and Oncology (the former chair of the international committee). He has been working for Japan Children’s Cancer Group, the first nationwide study group for childhood cancer in Japan launched in 2014. He is a physician with more than 30 years’ experiences of the practice and human resource development in the field of pediatric hematology/oncology, social care for children with cancer and their families, and translational research in pharmacology. He has also joined international medical cooperation with resource-limited countries in Africa as an expert of Japan International Co-operation Agency and has a strong will to contribute to the WHO Global Initiative for Childhood Cancer as a member of SIOP.